AJANTA PHARMA LTD.

Aayush Agrawal, a promoter of Ajanta Pharma Limited and trustee of Aayush Agrawal Trust, has created a pledge on 28,55,925 shares, representing 2.29% of the total share capital. This action was taken on June 2, 2026, to secure a new loan. The disclosure was made to BSE and NSE on June 4, 2026, in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. This move indicates the promoter's need for financing, potentially impacting their direct control or liquidity associated with these shares.

Gabs Investments Pvt Ltd, a promoter of Ajanta Pharma Limited, has created a pledge on 27,70,000 shares, representing 2.22% of the company's total share capital. This action was taken to secure a new loan. The disclosure was made on June 3, 2026, in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The shares have been pledged to CTL Trusteeship Limited.

Ajanta Pharma Limited promoter Ravi Agrawal, acting as a trustee for the Ravi Agrawal Trust, has disclosed the creation and release of share pledges. The promoter released a total of 2,60,000 equity shares from pledge and created a new pledge on 2,20,000 equity shares. The transactions were conducted for re-financing purposes, with the release attributed to excess pledge. The post-event encumbered holding for the Ravi Agrawal Trust stands at 6,023,920 shares, representing 4.82% of the total share capital.

Ajanta Pharma Ltd has revised its schedule for Analyst / Institutional Investor Meetings, initially announced under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The dates of two conferences were inadvertently interchanged in the earlier intimation. The corrected schedule includes participation in the 360 ONE Capital(B&K) Annual Investor Conference on May 29, 2026, and the ICICI Securities India Investor Conference on June 8, 2026. The schedule is subject to change due to unforeseen circumstances, and discussions will be based on publicly available information.

Ajanta Pharma Ltd. announced its participation in investor conferences. The company will attend the ICICI Securities India Investor Conference on May 29, 2026, at the Grand Hyatt, Santacruz, and the 360 ONE Capital(B&K) Annual Investor Conference on June 8, 2026. Discussions will be based on already published information. The schedule is subject to change due to unforeseen circumstances.

Ajanta Pharma Limited's promoter, Aayush Agrawal (trustee of Aayush Agrawal Trust), has disclosed the creation and simultaneous release of pledges on 2,86,213 equity shares each. The pledge creation was undertaken to secure a new loan, while the release of an equivalent number of shares from pledge was due to the repayment of an existing loan. Both transactions occurred on May 12, 2026, with Julius Baer Capital (India) Pvt Ltd. This disclosure was made to the stock exchanges on May 13, 2026, in compliance with Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Ajanta Pharma Ltd. has re-appointed M/s. Aneja Assurance Pvt. Ltd. as Internal Auditors, M/s. RA & Co. as Cost Auditors, and M/s. R S Sanghai & Associates as Tax Auditors for the financial year 2026-27. The re-appointments were approved at the Board meeting held on May 5, 2026, and are subject to ratification of the cost auditor's remuneration by the company's members. There are no disclosed relationships between the directors and the auditors.

Ajanta Pharma Ltd reported strong FY26 results with revenue from operations up 17% to ₹5,453 cr and profit after tax up 15% to ₹1,056 cr. Q4 FY26 revenue rose 21% to ₹1,422 cr, while PAT increased 18% to ₹267 cr. The company's India branded generics business exceeded IPM growth by 33%, driven by new launches and volume growth. Ajanta Pharma will host an earnings conference call on May 5, 2026.

Ajanta Pharma Ltd. reported its audited consolidated financial results for the year ended March 31, 2026. The company's revenue from operations increased by 17% to ₹5,453 cr, while profit after tax (PAT) rose by 15% to ₹1,056 cr. The Board meeting was held on May 5, 2026, where the results were approved. The company will host an earnings conference call on the same day to discuss the financial performance.

Ajanta Pharma Ltd. announced that the US FDA concluded an inspection at its manufacturing facility in Paithan, Maharashtra. The inspection, conducted from April 13 to April 21, 2026, resulted in the issuance of Form-483 with five observations. The company has stated its intention to respond to the US FDA within the specified timeframe. This development is significant for investors as regulatory compliance, particularly with the US FDA, is crucial for pharmaceutical companies' operations and market access.